Last Updated :2025/07/10
Research activity information
Paper
- Nocturnal baricitinib administration leads to rapid drug responses in rheumatoid arthritis: a multicenter non-randomized controlled study.
Teppei Hashimoto; Kazuyuki Tsuboi; Takeo Abe; Takahiro Yoshikawa; Kazuteru Noguchi; Tetsuya Furukawa; Koji Tateishi; Yasuhiro Terashima; Nao Sibanuma; Naoto Azuma; Takashi Yamane; Kiyoshi Matsui; Akira Hashiramoto
Arthritis research & therapy, Apr. 2025 - Oral health-related quality of life in Sjögren's disease patients with unstimulated whole salivary flows ≥0.1 mL/min for whom no therapeutic approaches are provided in the EULAR recommendations.
Naoto Azuma; Maki Iwatani; Yuichi Yokoyama; Naoaki Hashimoto; Masao Tamura; Teppei Hashimoto; Mai Morimoto; Aki Nishioka; Masayasu Kitano; Shinichiro Tsunoda; Takashi Yamane; Kiyoshi Matsui; Hajime Sano
Modern rheumatology, Mar. 2025 - Clinical course and flare predictors in patients with rheumatoid arthritis in low disease activity and ultrasound remission monitored by ultrasound yearly and on-demand: A prospective 2-year observation study.
Takeo Abe; Masao Tamura; Kazuyuki Tsuboi; Yuko Minagawa; Kazuteru Noguchi; Chie Ogita; Teppei Hashimoto; Naoto Azuma; Kiyoshi Matsui
Reumatologia clinica, Dec. 2024 - SAPHO症候群30例の臨床的特徴と血清サイトカイン値に基づくクラスター分析
田村 誠朗; 吉川 卓宏; 北島 一宏; 古川 哲也; 橋本 哲平; 東 直人; 山門 亨一郎; 松井 聖
兵庫医科大学医学会雑誌, Mar. 2024 - Involvement of YKL-40-positive macrophages commonly identified in polymyositis and dermatomyositis in the pathogenesis of myositis: a retrospective study.
Kazuteru Noguchi; Tetsuya Furukawa; Yoshiki Tatsumi; Shuhei Kasama; Takahiro Yoshikawa; Teppei Hashimoto; Naoto Azuma; Seiichi Hirota; Takashi Kimura; Kiyoshi Matsui
Immunological medicine, Mar. 2024 - Association of Baseline Serum Soluble Tumour Necrosis Factor Receptor Levels with the Response of Rheumatoid Arthritis to Janus Kinase Inhibitor Therapy.
Takahiro Yoshikawa; Tetsuya Furukawa; Teppei Hashimoto; Naoto Azuma; Kiyoshi Matsui
International journal of rheumatology, 2024 - Tocilizumab suppresses NF-kappa B activation via toll-like receptor 9 signaling by reducing cell-free DNA in rheumatoid arthritis.
Teppei Hashimoto; Kohsuke Yoshida; Yuichi Yokoyama; Naonori Hashimoto; Kenta Kaneshiro; Takahiro Yoshikawa; Koji Tateishi; Yasuhiro Terashima; Kiyoshi Matsui; Akira Hashiramoto
Clinical and experimental immunology, Jul. 2023 - [COMPONENT ANALYSIS OF THREE ANISAKIASIS ALLERGY CASES IN OUR DEPARTMENT].
Masao Tamura; Kuniyoshi Shimakura; Yukihiro Kobayashi; Takahiro Yoshikawa; Teppei Hashimoto; Naoto Azuma; Kiyoshi Matsui
Arerugi = [Allergy], 2023 - Serum B cell activating factor (BAFF) as a biomarker for induction of remission with rituximab in ANCA-associated vasculitis.
Kazuyuki Tsuboi; Kazuteru Noguchi; Masayasu Kitano; Tetsuya Furukawa; Teppei Hashimoto; Naoto Azuma; Kiyoshi Matsui
Immunological medicine, Dec. 2022 - Cell-Free DNA in Rheumatoid Arthritis.
Teppei Hashimoto; Kohsuke Yoshida; Akira Hashiramoto; Kiyoshi Matsui
International journal of molecular sciences, Aug. 2021 - Increased Circulating Cell-Free DNA in Eosinophilic Granulomatosis With Polyangiitis: Implications for Eosinophil Extracellular Traps and Immunothrombosis.
Teppei Hashimoto; Shigeharu Ueki; Yosuke Kamide; Yui Miyabe; Mineyo Fukuchi; Yuichi Yokoyama; Tetsuya Furukawa; Naoto Azuma; Nobuyuki Oka; Hiroki Takeuchi; Kyoko Kanno; Akemi Ishida-Yamamoto; Masami Taniguchi; Akira Hashiramoto; Kiyoshi Matsui
Frontiers in immunology, 2021 - Acquired marked hypertriglyceridemia with anti-GPIHBP1 antibodies.
Minami Imai; Hiroyasu Yamamoto; Teppei Hashimoto; Hidenori Koyama; Shinji Kihara
Pediatrics international : official journal of the Japan Pediatric Society, May 2020 - Expressions of circadian clock genes represent disease activities of RA patients treated with biological DMARDs.
Kenta Kaneshiro; Kohsuke Yoshida; Kanta Morii; Yuto Oketani; Koto Uchida; Arisa Yaekura; Ikumi Okumura; Teppei Hashimoto; Yoshiko Kawasaki; Nao Shibanuma; Yoshitada Sakai; Akira Hashiramoto
Modern rheumatology, Mar. 2020 - Methotrexate upregulates circadian transcriptional factors PAR bZIP to induce apoptosis on rheumatoid arthritis synovial fibroblasts.
Kohjin Suzuki; Kohsuke Yoshida; Takeshi Ueha; Kenta Kaneshiro; Ayako Nakai; Naonori Hashimoto; Koto Uchida; Teppei Hashimoto; Yoshiko Kawasaki; Nao Shibanuma; Natsuko Nakagawa; Yoshitada Sakai; Akira Hashiramoto
Arthritis research & therapy, Mar. 2018 - TNF-α induces expression of the circadian clock gene Bmal1 via dual calcium-dependent pathways in rheumatoid synovial cells.
Kohsuke Yoshida; Ayako Nakai; Kenta Kaneshiro; Naonori Hashimoto; Kohjin Suzuki; Koto Uchida; Teppei Hashimoto; Yoshiko Kawasaki; Koji Tateishi; Natsuko Nakagawa; Nao Shibanuma; Yoshitada Sakai; Akira Hashiramoto
Biochemical and biophysical research communications, Jan. 2018 - Circulating cell free DNA: a marker to predict the therapeutic response for biological DMARDs in rheumatoid arthritis.
Teppei Hashimoto; Kohsuke Yoshida; Naonori Hashimoto; Ayako Nakai; Kenta Kaneshiro; Kohjin Suzuki; Yoshiko Kawasaki; Nao Shibanuma; Akira Hashiramoto
International journal of rheumatic diseases, Jun. 2017 - Circadian rhythm and joint stiffness/destruction in rheumatoid arthritis
Kohsuke Yoshida; Teppei Hashimoto; Yoshitada Sakai; Akira Hashiramoto
International Journal of Clinical Rheumatology, Oct. 2015 - Involvement of the circadian rhythm and inflammatory cytokines in the pathogenesis of rheumatoid arthritis.
Kohsuke Yoshida; Teppei Hashimoto; Yoshitada Sakai; Akira Hashiramoto
Journal of immunology research, 2014 - Shorter disease duration is important for tocilizumab to achieve Boolean remission.
Yoshiko Kawasaki; Teppei Hashimoto; Takaichi Okano; Yoshitada Sakai; Takashi Yamane; Kazuko Shiozawa; Shunichi Shiozawa; Akira Hashiramoto
Modern rheumatology, Nov. 2013 - アダリムマブ アダリムマブの治療成績と、併用抗リウマチ薬の検討
田中 千尋; 柱本 照; 酒井 良忠; 鍵谷 真希; 川崎 善子; 橋本 哲平; 柴沼 均; 立石 耕司; 山根 隆志; 横山 公信; 松田 茂; 村田 美紀; 寺島 康浩; 香山 幸造; 中川 夏子; 吉原 良祐; 田中 泰史; 塩沢 和子; 塩澤 俊一
日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, Jun. 2011
MISC
- Survey on switching from a subcutaneous syringe to an autoinjection pen for the administration of adalimumab（Humira®）in patients with rheumatic diseases
Suzuki Emu; Azuma Naoto; Tamura Masao; Morimoto Mai; Yoshikawa Takahiro; Yokoyama Yuichi; Furukawa Tetsuya; Ogita Chie; Hashimoto Teppei; Matsui Kiyoshi; Hashimoto Naoaki
Clinical Rheumatology and Related Research, 2022 - The patient with Necrotic myopathy who exhibited head down condition as the chief symptom
Noguchi Kazuteru; Hashimoto Teppei; Ogita Chie; Azuma Naoto; Matsui Kiyoshi; Tokuhara Yusuke; Kasama Shuhei; Yoshikawa Hiroo; Kitano Masayasu
Clinical Rheumatology and Related Research, 2021 - A study of adalimumab treatment for rheumatoid arthritis: analysis of the clinical course and the effect on joint destruction
Shiozawa Kazuko; Tanaka Yasushi; Yoshihara Ryousuke; Nakagawa Natsuko; Kouyama Kouzou; Murata Miki; Terashima Yasuhiro; Tanaka Chihiro; Yamane Takashi; Matsuda Shigeru; Yokoyama Kiminobu; Tateishi Kouji; You Noriaki; Hashimoto Teppei; Hashiramoto Teru; Shiozawa Shunnichi
Clinical Rheumatology and Related Research, 2011
Research Themes
- Role of the clock genes in rheumatoid arthritis
Grant-in-Aid for Young Scientists (B)
Kobe University
01 Apr. 2014 - 31 Mar. 2016
